Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc develops and manufactures therapeutic medical devices and healthcare technology for chronic diseases and procedural care. Its news commonly covers regulatory clearances and CE marks, product launches, clinical data, acquisitions, and financial results across cardiovascular, cardiac rhythm management, cranial and spinal technologies, surgical navigation, robotics, and ablation systems.
Recent company updates include the Stealth AXiS™ surgical system for planning, navigation, and robotics; the Affera™ mapping and ablation system with Sphere-9™ and Sphere-360™ catheters; the OmniaSecure™ defibrillation lead; and the completed CathWorks acquisition, including the FFRangio® System for coronary artery disease assessment.
Medtronic (NYSE: MDT) announced multiple U.S. milestones for its Hugo™ robotic-assisted surgery (RAS) system, aimed at expanding into general and gynecologic surgery.
The company submitted 510(k)s for general and gynecologic indications and the LigaSure™ RAS Maryland instrument, received 510(k) clearance for ProGrip™ Advanced mesh for robotic ventral hernia repair, and completed enrollment in the Embrace Gynecology IDE study.
Medtronic (NYSE: MDT) announced strategic investments in two ICE catheter developers, Beluga Medical in California and CardioACC in Shenzhen, China, to support future expansion of its cardiac ablation portfolio.
Medtronic plans to integrate intracardiac echocardiography into its Affera mapping and ablation system to enhance electrophysiology workflows and strengthen the Affera ecosystem.
Medtronic (NYSE: MDT) reported Q4 FY26 revenue of $9.8 billion, up 9.9% reported and 6.6% organic, with non-GAAP EPS of $1.55. FY26 revenue reached $36.4 billion, up 8.4% reported and 5.8% organic, and GAAP EPS was $3.73, up 3.3%.
Cash from operations was $7.3 billion and free cash flow $5.4 billion. The quarterly dividend was raised to $0.72 per share, the 49th consecutive annual increase. FY27 guidance calls for 6.75%-7.25% organic revenue growth and non-GAAP EPS of $5.90-$6.00.
morph launched a physically intelligent soft robotics cells platform that embeds sensing and adaptive control into deformable materials, enabling real‑time changes in shape and stiffness for safer human interaction.
Backed by investors including 8VC and Pharrell Williams, morph targets athletic performance, injury prevention, mobility support, and future applications in healthcare, automotive, and industrial safety via a B2B partnership model.
Medtronic (NYSE: MDT) plans to acquire SPR Therapeutics, a leader in temporary peripheral nerve stimulation (PNS) for chronic pain, for approximately $650 million in cash.
The deal would add SPR’s 60-day, FDA-cleared SPRINT PNS System to Medtronic’s neuromodulation portfolio, with closing expected in the first half of Fiscal 2027, subject to regulatory approvals.
Medtronic (MDT) received CE mark for the Stealth AXiS™ surgical system on April 28, 2026, authorizing use across Europe for spine and cranial procedures. The platform integrates planning, navigation, and robotics with LiveAlign™ segmental tracking and AI-driven planning as part of the AiBLE™ ecosystem.
This follows U.S. FDA clearances earlier in 2026 and is positioned to expand access to integrated surgical workflows across diverse European healthcare systems.
Medtronic (NYSE: MDT) reported interim clinical and regulatory milestones for the Affera system and Sphere catheters on April 25, 2026. Key data: 65.5% of VT patients were free from recurrence at six months; FDA granted Breakthrough Device designation for Sphere-9 and approved a U.S. pivotal IDE. Sphere-360 showed 100% lesion durability in left common pulmonary veins subanalysis, has CE Mark (Jan 2026), and a U.S. IDE is enrolling. First patient enrolled in Conquer-AF to study Sphere-9 in repeat AFib ablations.
Medtronic (NYSE:MDT) completed its acquisition of CathWorks on April 20, 2026, valuing the deal at $585 million with potential undisclosed earn-outs. The purchase adds the CathWorks FFRangio® System—an AI-driven, drug-free, wire-free angiography-derived physiologic assessment—commercially available in the U.S., Europe and Japan.
The ALL-RISE randomized trial (1,900+ patients) showed FFRangio is non-inferior to wire-based FFR for one-year MACE, supporting clinical adoption; Medtronic says the deal is immaterial to FY2027 GAAP and adjusted EPS and neutral to accretive thereafter.
Medtronic (NYSE: MDT) will report fourth quarter and full fiscal year 2026 results on Wednesday, June 3, 2026. The company ends its fiscal year on April 24, 2026.
A news release with summary financial information will be issued at 5:45 a.m. Central Time, followed by a video webcast at 6:45 a.m. CT. A replay and transcript will be posted within 24 hours at the investor relations events page. Contacts for media and investor relations are provided.
Medtronic (NYSE: MDT) received FDA clearance for the Stealth AXiS™ surgical system for cranial and ENT procedures on March 27, 2026. The system unifies planning, navigation, robotics and AI-enabled tractography inside the AiBLE™ ecosystem, and was cleared for spine in February.
The platform integrates intraoperative ultrasound via GE HealthCare bkActiv™ and is designed for continuous software innovation and multi-specialty connectivity.